Drägerwerk AG & Co. KGaA Q4 Earnings Call Highlights

• Record income and profitability: Drägerwerk reported grounds nett income of astir EUR 3.5 billion and EBIT roseate much than 20% to astir EUR 233 million, outperforming forecasts contempt “opposing effects” of implicit EUR 90 million from tariffs, FX and the lack of prior-year one-offs.

• Division rebound: The Medical part saw astir 9% bid maturation with EBIT doubling to astir EUR 57 million, portion Safety delivered unchangeable margins and EBIT of astir EUR 176 million with orders up much than 6%.

• Stronger currency position, higher payout and 2026 guidance: Free currency travel was astir EUR 120 million, nett fiscal indebtedness fell ~25% to EUR 123 million, the dividend was raised to EUR 2.21/EUR 2.27, and 2026 guidance targets currency-adjusted income maturation of 2–6% with an EBIT borderline of 5–7.5%.

• Interested successful Drägerwerk AG & Co. KGaA? Here are 5 stocks we similar better.

Drägerwerk AG & Co. KGaA (ETR:DRW3) reported grounds nett income and sharply higher net for fiscal 2025, with absorption pointing to broad-based request crossed some divisions and each regions contempt important headwinds from tariffs and currency movements.

CEO Stefan Dräger said the institution generated the highest nett income successful its past astatine astir EUR 3.5 billion, somewhat supra its latest forecast and astir EUR 25 million higher than the pandemic-driven precocious successful 2020. He emphasized that the caller grounds was achieved “entirely without a peculiar economical situation.”

→ Planet Labs: The Satellite Stock That Keeps Shooting to the Moon

Earnings earlier involvement and taxes (EBIT) roseate by much than 20% to astir EUR 233 million, with the EBIT borderline improving astir 1 percent constituent to 6.7%, besides supra the company’s astir caller forecast. CFO Gert-Hartwig Lescow said the results reflected precocious bid intake, beardown year-end concern momentum, and an improved gross margin.

Orders accrued 7.7% to astir EUR 3.6 billion connected a currency-adjusted basis, with some divisions contributing. Lescow added that the Americas and EMEA regions were the largest maturation drivers for some orders and sales.

→ Active ETFs Surge Past Passive, and These Are successful the Lead

Management highlighted that 2025 results came against a tougher backdrop compared with 2024, erstwhile EBIT benefited from one-off gains including the merchantability of a non-strategic fume and occurrence alarm systems concern successful the Netherlands and existent property successful the U.S.

In 2025, the institution faced headwinds from U.S. import tariffs and currency impacts. Stefan Dräger said tariffs imposed by the U.S. authorities reduced EBIT by astir EUR 26 million (about EUR 21 cardinal successful Medical and EUR 5 cardinal successful Safety). Currency effects were described arsenic totaling astir EUR 45 million successful EBIT impact, with the bulk attributed to the Medical division. Management summarized the combined headwinds, including the lack of prior-year one-offs, arsenic “opposing effects of much than EUR 90 million,” which the institution said it “overcompensated” done operating performance.